JP2022169780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022169780A5 JP2022169780A5 JP2022138972A JP2022138972A JP2022169780A5 JP 2022169780 A5 JP2022169780 A5 JP 2022169780A5 JP 2022138972 A JP2022138972 A JP 2022138972A JP 2022138972 A JP2022138972 A JP 2022138972A JP 2022169780 A5 JP2022169780 A5 JP 2022169780A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical combination
- combination according
- inhibitor
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003301 nivolumab Drugs 0.000 claims 5
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 4
- 229960002621 pembrolizumab Drugs 0.000 claims 4
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Claims (8)
- レゴラフェニブまたはその水和物、溶媒和物または薬学的に許容される塩と、ＰＤ－１阻害剤を含む組み合わせ医薬であって、
ＰＤ－１阻害剤が、抗ＰＤ－１抗体である、組み合わせ医薬。 - ＰＤ－１阻害剤が、ニボルマブ（Ｏｐｄｉｖｏ、ＢＭＳ－９３６５５８、ＭＤＸ１１０６）、ペンブロリズマブ（Ｋｅｙｔｒｕｄａ、ＭＫ－３４７５、ランブロリズマブ）、ピディリズマブ（ＣＴ－０１１）、ＰＤＲ－００１、ＪＳ００１、ＳＴＩ－Ａ１１１０、ＡＭＰ－２２４およびＡＭＰ－５１４（ＭＥＤＩ０６８０）からなる群から選択される抗ＰＤ－１抗体である、請求項１に記載の組み合わせ医薬。
- ＰＤ－１阻害剤が、ニボルマブである、請求項２に記載の組み合わせ医薬。
- 互いに分離した成分を含む組み合わせパックである、請求項１～３のいずれか１項に記載の組み合わせ医薬。
- 同じ疾患の治療に使用するために、成分が別々の剤形で同時にまたは連続して投与される、請求項１～４のいずれか１項に記載の組み合わせ医薬。
- 過剰増殖性障害治療用薬剤として使用するための、請求項１～５のいずれか１項に記載の組み合わせ医薬。
- 過剰増殖性障害が、乳房の癌、気道の癌、脳の癌、生殖器官の癌、消化管の癌、尿路の癌、目の癌、肝臓の癌、皮膚の癌、頭頸部の癌、甲状腺の癌および副甲状腺の癌ならびにそれらの遠隔転移からなる群から選択される、請求項６に記載の組み合わせ医薬。
- 過剰増殖性障害が、肝細胞癌、大腸癌および消化管間質腫瘍（ＧＩＳＴ）からなる群から選択される、請求項６に記載の組み合わせ医薬。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174169.7 | 2017-06-02 | ||
| EP17174169 | 2017-06-02 | ||
| PCT/EP2018/063785 WO2018219807A1 (en) | 2017-06-02 | 2018-05-25 | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
| JP2019565949A JP7303122B2 (ja) | 2017-06-02 | 2018-05-25 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565949A Division JP7303122B2 (ja) | 2017-06-02 | 2018-05-25 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022169780A JP2022169780A (ja) | 2022-11-09 |
| JP2022169780A5 true JP2022169780A5 (ja) | 2023-01-27 |
| JP7475402B2 JP7475402B2 (ja) | 2024-04-26 |
Family
ID=58992733
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565949A Active JP7303122B2 (ja) | 2017-06-02 | 2018-05-25 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
| JP2022138972A Active JP7475402B2 (ja) | 2017-06-02 | 2022-09-01 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565949A Active JP7303122B2 (ja) | 2017-06-02 | 2018-05-25 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11951166B2 (ja) |
| EP (2) | EP4342542A3 (ja) |
| JP (2) | JP7303122B2 (ja) |
| CN (3) | CN110662540B (ja) |
| AU (2) | AU2018276273B2 (ja) |
| BR (1) | BR112019025478A8 (ja) |
| CA (1) | CA3065125A1 (ja) |
| DK (1) | DK3630112T3 (ja) |
| FI (1) | FI3630112T3 (ja) |
| IL (1) | IL270948A (ja) |
| LT (1) | LT3630112T (ja) |
| MX (1) | MX2023001721A (ja) |
| PT (1) | PT3630112T (ja) |
| WO (1) | WO2018219807A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3630112T (lt) | 2017-06-02 | 2024-05-10 | Bayer Healthcare Llc | Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymui |
| CN111001004A (zh) * | 2019-10-08 | 2020-04-14 | 广州医科大学附属第二医院 | 一种治疗肝癌的药物组合及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004010407T2 (de) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden |
| JP2009514921A (ja) | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 糖尿病性神経障害を処置するためのジアリールウレア |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| UY35006A (es) * | 2012-09-06 | 2014-03-31 | Bayer Healthcare Llc | Composición farmacéutica recubierta que contiene regorafenib |
| RS57875B1 (sr) * | 2012-09-25 | 2018-12-31 | Bayer Pharma AG | Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera |
| JP5653489B1 (ja) | 2013-07-24 | 2015-01-14 | 三菱エンジニアリングプラスチックス株式会社 | 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法 |
| ES2899457T3 (es) | 2014-02-04 | 2022-03-11 | Pfizer | Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer |
| EP3338800A1 (en) | 2014-02-21 | 2018-06-27 | IDAC Theranostics, Inc. | Therapeutic agent for solid cancer |
| SG10202007111TA (en) * | 2014-07-15 | 2020-09-29 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| WO2016010879A1 (en) | 2014-07-15 | 2016-01-21 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| BR112017002807A2 (pt) * | 2014-08-19 | 2017-12-19 | Nat Univ Corporation Okayama Univ | método para aprimorar a função de célula imune e método para avaliar a mulfuncionalidade de célula imune |
| EP3200775B1 (en) | 2014-10-03 | 2019-11-20 | Novartis AG | Combination therapies |
| AU2015346295A1 (en) | 2014-11-13 | 2017-05-25 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| WO2016173959A1 (en) * | 2015-04-28 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Regorafenib for treating colorectal cancer |
| US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
| WO2017210119A1 (en) | 2016-06-03 | 2017-12-07 | Imclone Llc | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| LT3630112T (lt) | 2017-06-02 | 2024-05-10 | Bayer Healthcare Llc | Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymui |
| AU2018282094A1 (en) * | 2017-06-05 | 2019-12-12 | Janssen Biotech, Inc. | Antibodies that specifically bind PD-1 and methods of use |
-
2018
- 2018-05-25 LT LTEPPCT/EP2018/063785T patent/LT3630112T/lt unknown
- 2018-05-25 EP EP24150061.0A patent/EP4342542A3/en active Pending
- 2018-05-25 CN CN201880036504.5A patent/CN110662540B/zh active Active
- 2018-05-25 FI FIEP18725258.0T patent/FI3630112T3/fi active
- 2018-05-25 BR BR112019025478A patent/BR112019025478A8/pt unknown
- 2018-05-25 WO PCT/EP2018/063785 patent/WO2018219807A1/en active Application Filing
- 2018-05-25 PT PT187252580T patent/PT3630112T/pt unknown
- 2018-05-25 EP EP18725258.0A patent/EP3630112B1/en active Active
- 2018-05-25 AU AU2018276273A patent/AU2018276273B2/en active Active
- 2018-05-25 JP JP2019565949A patent/JP7303122B2/ja active Active
- 2018-05-25 CN CN202410088226.5A patent/CN117899212A/zh active Pending
- 2018-05-25 CA CA3065125A patent/CA3065125A1/en active Pending
- 2018-05-25 CN CN202311446796.9A patent/CN117582495A/zh active Pending
- 2018-05-25 US US16/617,642 patent/US11951166B2/en active Active
- 2018-05-25 DK DK18725258.0T patent/DK3630112T3/da active
-
2019
- 2019-11-26 IL IL270948A patent/IL270948A/en unknown
- 2019-12-02 MX MX2023001721A patent/MX2023001721A/es unknown
- 2019-12-31 US US16/731,409 patent/US20200155674A1/en not_active Abandoned
- 2019-12-31 US US16/731,412 patent/US11517622B2/en active Active
-
2022
- 2022-01-14 US US17/576,522 patent/US20220133888A1/en active Pending
- 2022-09-01 JP JP2022138972A patent/JP7475402B2/ja active Active
-
2023
- 2023-12-12 AU AU2023282197A patent/AU2023282197A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022169780A5 (ja) | ||
| JP2015529234A5 (ja) | ||
| ES2687985T3 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer colorrectal | |
| JP2015511609A5 (ja) | ||
| JP2018109022A5 (ja) | ||
| HRP20200180T1 (hr) | Derivati (aza-)izokinolinona | |
| JP2018513107A5 (ja) | ||
| JP2015524472A5 (ja) | ||
| JP2014509659A5 (ja) | ||
| JP2014512355A5 (ja) | ||
| JP2015536986A5 (ja) | ||
| JP2014512354A5 (ja) | ||
| JP2016528162A5 (ja) | ||
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| JP2010524957A5 (ja) | ||
| JP2016515628A5 (ja) | ||
| JP2015517523A5 (ja) | ||
| JP2014525454A5 (ja) | ||
| JP2015510916A5 (ja) | ||
| JP2020515578A5 (ja) | ||
| HRP20171783T1 (hr) | Derivati imidazopirazinona | |
| AU2015301097A1 (en) | Drug combinations to treat multiple myeloma | |
| JP2020521786A5 (ja) | ||
| Hamilton et al. | Tarascon pharmacopoeia | |
| JP2020515523A5 (ja) |